Safety and efficacy of anti-il6-receptor tocilizumab use in severe and critical patients affected by coronavirus disease 2019: A comparative analysis

BACKGROUND: As the novel SARS-CoV-2 pandemic occurred, no specific treatment was yet available. Inflammatory response secondary to viral infection might be the driver of severe diseases. We report the safety and efficacy (in terms of overall survival and hospital discharge) of the anti-IL6 tocilizum...

Descripción completa

Detalles Bibliográficos
Autores principales: Rossotti, Roberto, Travi, Giovanna, Ughi, Nicola, Corradin, Matteo, Baiguera, Chiara, Fumagalli, Roberto, Bottiroli, Maurizio, Mondino, Michele, Merli, Marco, Bellone, Andrea, Basile, Andriano, Ruggeri, Ruggero, Colombo, Fabrizio, Moreno, Mauro, Pastori, Stefano, Perno, Carlo Federico, Tarsia, Paolo, Epis, Oscar Massimiliano, Puoti, Massimo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The British Infection Association. Published by Elsevier Ltd. 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7345400/
https://www.ncbi.nlm.nih.gov/pubmed/32652164
http://dx.doi.org/10.1016/j.jinf.2020.07.008

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7345400/
https://www.ncbi.nlm.nih.gov/pubmed/32652164
http://dx.doi.org/10.1016/j.jinf.2020.07.008

Ejemplares similares